Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,671
  • Shares Outstanding, K 22,226
  • Annual Sales, $ 710 K
  • Annual Income, $ -11,900 K
  • EBIT $ -9 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.63
  • Price/Sales 33.37
  • Price/Cash Flow N/A
  • Price/Book 7.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9678 +15.73%
on 11/17/25
1.2063 -7.15%
on 11/05/25
+0.0100 (+0.90%)
since 11/04/25
3-Month
0.8003 +39.95%
on 10/17/25
1.5500 -27.74%
on 09/25/25
+0.1546 (+16.01%)
since 09/04/25
52-Week
0.7749 +44.53%
on 08/22/25
2.6100 -57.09%
on 12/05/24
-1.4700 (-56.76%)
since 12/04/24

Most Recent Stories

More News
Lexaria Bioscience Expands Strategic Outreach and Secures New Patents

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lexaria Bioscience...

LEXX : 1.1200 (+0.90%)
Fed Meeting, U.S. Jobs in Focus for This Week

Tuesday U.S. Economic Lookahead NFIB optimism index (June) Consumer credit (May) ...

AZZ : 106.78 (+0.91%)
SAR : 22.76 (+1.43%)
CAG : 16.95 (-1.22%)
MTY.TO : 37.69 (+0.13%)
UNTY : 52.15 (-0.10%)
LEXX : 1.1200 (+0.90%)
PENG : 21.68 (+0.93%)
DAL : 67.24 (-0.37%)
BSET : 15.61 (+0.13%)
LEVI : 22.19 (-1.11%)
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Lexaria Announces $2 Million Registered Direct Offering of Common Stock

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Lexaria's Human GLP-1 Study #5 Begins Dosing

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria executing a triple-pronged strategy in obesity and diabetes

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

LEXXW : 0.0252 (-0.79%)
LEXX : 1.1200 (+0.90%)

Business Summary

Lexaria Bioscience Corp. provides drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way Active Pharmaceutical Ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules....

See More

Key Turning Points

3rd Resistance Point 1.2900
2nd Resistance Point 1.2300
1st Resistance Point 1.1750
Last Price 1.1200
1st Support Level 1.0600
2nd Support Level 1.0000
3rd Support Level 0.9450

See More

52-Week High 2.6100
Fibonacci 61.8% 1.9090
Fibonacci 50% 1.6924
Fibonacci 38.2% 1.4759
Last Price 1.1200
52-Week Low 0.7749

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar